Apadamtase Alfa: First Approval

Abstract

KeyPoints • A human recombinant form of ADAMTS13 is being developed by Takeda (under license from KM biologics) for TTP and sickle cell disease • Received its first approval on 9 November 2023 in the USA • Approved for use as prophylactic or ondemand ERT in paediatric and adult patients with congenital TTP This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, please see the full text online.